Home > > > > Report Detail

Global Biologics and Biosimilars Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Publisher Name :
Date: 06-Sep-2022
No. of pages: 124
Inquire Before Buying

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products, and can be manufactured when the original product's patent expires.

Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Biologics and Biosimilars market is projected to reach US$ 274800 million by 2028 from an estimated US$ 203890 million in 2022, at a CAGR of 5.1% during 2023 and 2028.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.

The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics and Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

- Roche

- Amgen

- AbbVie

- Sanofi-Aventis

- Johnson & Johnson

- Pfizer

- Novo Nordisk

- Eli Lilly

- Novartis

- Merck

- 3sbio

- Changchun High Tech

- CP Guojian

- Biotech

- Gelgen

- Innovent

- Dong Bao

- Ganlee

- United Laboratories

Product Type Insights

Global markets are presented by Biologics and Biosimilars type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Biologics and Biosimilars are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Biologics and Biosimilars Segment by Type

- Monoclonal Antibodies

- Interferon

- Erythropoietin

- Insulin

- Vaccines

- Others

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Biologics and Biosimilars market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biologics and Biosimilars market.

Biologics and Biosimilars Segment by Application

- Tumor

- Diabetes

- Cardiovascular

- Hemophilia

- Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic Countries

- - Benelux

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Southeast Asia

- - Australia

- - Rest of Asia-Pacific

- Latin America

- - Mexico

- - Brazil

- - Argentina

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of Middle East & Africa

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Biologics and Biosimilars market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biologics and Biosimilars industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution

Global Biologics and Biosimilars Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Table of Contents
1 Study Coverage
1.1 Biologics and Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Biologics and Biosimilars Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Market by Application
1.3.1 Global Biologics and Biosimilars Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biologics and Biosimilars Market Size Estimates and Forecasts
2.1.1 Global Biologics and Biosimilars Revenue 2017-2028
2.1.2 Global Biologics and Biosimilars Sales 2017-2028
2.2 Biologics and Biosimilars Market Size by Region: 2022 Versus 2028
2.3 Biologics and Biosimilars Sales by Region (2017-2028)
2.3.1 Global Biologics and Biosimilars Sales by Region: 2017-2022
2.3.2 Global Biologics and Biosimilars Sales Forecast by Region (2023-2028)
2.3.3 Global Biologics and Biosimilars Sales Market Share by Region (2017-2028)
2.4 Biologics and Biosimilars Market Estimates and Projections by Region (2023-2028)
2.4.1 Global Biologics and Biosimilars Revenue by Region: 2017-2022
2.4.2 Global Biologics and Biosimilars Revenue Forecast by Region (2023-2028)
2.4.3 Global Biologics and Biosimilars Revenue Market Share by Region (2017-2028)
3 Global Biologics and Biosimilars by Manufacturers
3.1 Global Top Biologics and Biosimilars Manufacturers by Sales
3.1.1 Global Biologics and Biosimilars Sales by Manufacturer (2017-2022)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Manufacturer (2017-2022)
3.2 Global Top Biologics and Biosimilars Manufacturers by Revenue
3.2.1 Global Biologics and Biosimilars Revenue by Manufacturer (2017-2022)
3.2.2 Global Biologics and Biosimilars Revenue Share by Manufacturer (2017-2022)
3.3 Global Biologics and Biosimilars Price by Manufacturer (2017-2022)
3.4 Competitive Landscape
3.4.1 Key Biologics and Biosimilars Manufacturers Covered: Ranking by Revenue
3.4.2 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.4.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Biologics and Biosimilars Manufacturing Base Distribution, Product Type
3.5.1 Biologics and Biosimilars Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Biologics and Biosimilars Product Type
3.5.3 Date of International Manufacturers Enter into Biologics and Biosimilars Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Roche
4.1.1 Roche Corporation Information
4.1.2 Roche Description, Business Overview
4.1.3 Roche Biologics and Biosimilars Products Offered
4.1.4 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.1.5 Roche Biologics and Biosimilars Sales by Product in 2021
4.1.6 Roche Biologics and Biosimilars Sales by Application in 2021
4.1.7 Roche Biologics and Biosimilars Sales by Geographic Area in 2021
4.1.8 Roche Recent Developments
4.2 Amgen
4.2.1 Amgen Corporation Information
4.2.2 Amgen Description, Business Overview
4.2.3 Amgen Biologics and Biosimilars Products Offered
4.2.4 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.2.5 Amgen Biologics and Biosimilars Sales by Product in 2021
4.2.6 Amgen Biologics and Biosimilars Sales by Application in 2021
4.2.7 Amgen Biologics and Biosimilars Sales by Geographic Area in 2021
4.2.8 Amgen Recent Developments
4.3 AbbVie
4.3.1 AbbVie Corporation Information
4.3.2 AbbVie Description, Business Overview
4.3.3 AbbVie Biologics and Biosimilars Products Offered
4.3.4 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.3.5 AbbVie Biologics and Biosimilars Sales by Product in 2021
4.3.6 AbbVie Biologics and Biosimilars Sales by Application in 2021
4.3.7 AbbVie Biologics and Biosimilars Sales by Geographic Area in 2021
4.3.8 AbbVie Recent Developments
4.4 Sanofi-Aventis
4.4.1 Sanofi-Aventis Corporation Information
4.4.2 Sanofi-Aventis Description, Business Overview
4.4.3 Sanofi-Aventis Biologics and Biosimilars Products Offered
4.4.4 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.4.5 Sanofi-Aventis Biologics and Biosimilars Sales by Product in 2021
4.4.6 Sanofi-Aventis Biologics and Biosimilars Sales by Application in 2021
4.4.7 Sanofi-Aventis Biologics and Biosimilars Sales by Geographic Area in 2021
4.4.8 Sanofi-Aventis Recent Developments
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson Corporation Information
4.5.2 Johnson & Johnson Description, Business Overview
4.5.3 Johnson & Johnson Biologics and Biosimilars Products Offered
4.5.4 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.5.5 Johnson & Johnson Biologics and Biosimilars Sales by Product in 2021
4.5.6 Johnson & Johnson Biologics and Biosimilars Sales by Application in 2021
4.5.7 Johnson & Johnson Biologics and Biosimilars Sales by Geographic Area in 2021
4.5.8 Johnson & Johnson Recent Developments
4.6 Pfizer
4.6.1 Pfizer Corporation Information
4.6.2 Pfizer Description, Business Overview
4.6.3 Pfizer Biologics and Biosimilars Products Offered
4.6.4 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.6.5 Pfizer Biologics and Biosimilars Sales by Product in 2021
4.6.6 Pfizer Biologics and Biosimilars Sales by Application in 2021
4.6.7 Pfizer Biologics and Biosimilars Sales by Geographic Area in 2021
4.6.8 Pfizer Recent Development
4.7 Novo Nordisk
4.7.1 Novo Nordisk Corporation Information
4.7.2 Novo Nordisk Description, Business Overview
4.7.3 Novo Nordisk Biologics and Biosimilars Products Offered
4.7.4 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.7.5 Novo Nordisk Biologics and Biosimilars Sales by Product in 2021
4.7.6 Novo Nordisk Biologics and Biosimilars Sales by Application in 2021
4.7.7 Novo Nordisk Biologics and Biosimilars Sales by Geographic Area in 2021
4.7.8 Novo Nordisk Recent Development
4.8 Eli Lilly
4.8.1 Eli Lilly Corporation Information
4.8.2 Eli Lilly Description, Business Overview
4.8.3 Eli Lilly Biologics and Biosimilars Products Offered
4.8.4 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.8.5 Eli Lilly Biologics and Biosimilars Sales by Product in 2021
4.8.6 Eli Lilly Biologics and Biosimilars Sales by Application in 2021
4.8.7 Eli Lilly Biologics and Biosimilars Sales by Geographic Area in 2021
4.8.8 Eli Lilly Recent Development
4.9 Novartis
4.9.1 Novartis Corporation Information
4.9.2 Novartis Description, Business Overview
4.9.3 Novartis Biologics and Biosimilars Products Offered
4.9.4 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.9.5 Novartis Biologics and Biosimilars Sales by Product in 2021
4.9.6 Novartis Biologics and Biosimilars Sales by Application in 2021
4.9.7 Novartis Biologics and Biosimilars Sales by Geographic Area in 2021
4.9.8 Novartis Recent Development
4.10 Merck
4.10.1 Merck Corporation Information
4.10.2 Merck Description, Business Overview
4.10.3 Merck Biologics and Biosimilars Products Offered
4.10.4 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.10.5 Merck Biologics and Biosimilars Sales by Product in 2021
4.10.6 Merck Biologics and Biosimilars Sales by Application in 2021
4.10.7 Merck Biologics and Biosimilars Sales by Geographic Area in 2021
4.10.8 Merck Recent Development
4.11 3sbio
4.11.1 3sbio Corporation Information
4.11.2 3sbio Description, Business Overview
4.11.3 3sbio Biologics and Biosimilars Products Offered
4.11.4 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.11.5 3sbio Biologics and Biosimilars Sales by Product in 2021
4.11.6 3sbio Biologics and Biosimilars Sales by Application in 2021
4.11.7 3sbio Biologics and Biosimilars Sales by Geographic Area in 2021
4.11.8 3sbio Recent Development
4.12 Changchun High Tech
4.12.1 Changchun High Tech Corporation Information
4.12.2 Changchun High Tech Description, Business Overview
4.12.3 Changchun High Tech Biologics and Biosimilars Products Offered
4.12.4 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.12.5 Changchun High Tech Biologics and Biosimilars Sales by Product in 2021
4.12.6 Changchun High Tech Biologics and Biosimilars Sales by Application in 2021
4.12.7 Changchun High Tech Biologics and Biosimilars Sales by Geographic Area in 2021
4.12.8 Changchun High Tech Recent Development
4.13 CP Guojian
4.13.1 CP Guojian Corporation Information
4.13.2 CP Guojian Description, Business Overview
4.13.3 CP Guojian Biologics and Biosimilars Products Offered
4.13.4 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.13.5 CP Guojian Biologics and Biosimilars Sales by Product in 2021
4.13.6 CP Guojian Biologics and Biosimilars Sales by Application in 2021
4.13.7 CP Guojian Biologics and Biosimilars Sales by Geographic Area in 2021
4.13.8 CP Guojian Recent Development
4.14 Biotech
4.14.1 Biotech Corporation Information
4.14.2 Biotech Description, Business Overview
4.14.3 Biotech Biologics and Biosimilars Products Offered
4.14.4 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.14.5 Biotech Biologics and Biosimilars Sales by Product in 2021
4.14.6 Biotech Biologics and Biosimilars Sales by Application in 2021
4.14.7 Biotech Biologics and Biosimilars Sales by Geographic Area in 2021
4.14.8 Biotech Recent Development
4.15 Gelgen
4.15.1 Gelgen Corporation Information
4.15.2 Gelgen Description, Business Overview
4.15.3 Gelgen Biologics and Biosimilars Products Offered
4.15.4 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.15.5 Gelgen Biologics and Biosimilars Sales by Product in 2021
4.15.6 Gelgen Biologics and Biosimilars Sales by Application in 2021
4.15.7 Gelgen Biologics and Biosimilars Sales by Geographic Area in 2021
4.15.8 Gelgen Recent Development
4.16 Innovent
4.16.1 Innovent Corporation Information
4.16.2 Innovent Description, Business Overview
4.16.3 Innovent Biologics and Biosimilars Products Offered
4.16.4 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.16.5 Innovent Biologics and Biosimilars Sales by Product in 2021
4.16.6 Innovent Biologics and Biosimilars Sales by Application in 2021
4.16.7 Innovent Biologics and Biosimilars Sales by Geographic Area in 2021
4.16.8 Innovent Recent Development
4.17 Dong Bao
4.17.1 Dong Bao Corporation Information
4.17.2 Dong Bao Description, Business Overview
4.17.3 Dong Bao Biologics and Biosimilars Products Offered
4.17.4 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.17.5 Dong Bao Biologics and Biosimilars Sales by Product in 2021
4.17.6 Dong Bao Biologics and Biosimilars Sales by Application in 2021
4.17.7 Dong Bao Biologics and Biosimilars Sales by Geographic Area in 2021
4.17.8 Dong Bao Recent Development
4.18 Ganlee
4.18.1 Ganlee Corporation Information
4.18.2 Ganlee Description, Business Overview
4.18.3 Ganlee Biologics and Biosimilars Products Offered
4.18.4 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.18.5 Ganlee Biologics and Biosimilars Sales by Product in 2021
4.18.6 Ganlee Biologics and Biosimilars Sales by Application in 2021
4.18.7 Ganlee Biologics and Biosimilars Sales by Geographic Area in 2021
4.18.8 Ganlee Recent Development
4.19 United Laboratories
4.19.1 United Laboratories Corporation Information
4.19.2 United Laboratories Description, Business Overview
4.19.3 United Laboratories Biologics and Biosimilars Products Offered
4.19.4 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2017-2022)
4.19.5 United Laboratories Biologics and Biosimilars Sales by Product in 2021
4.19.6 United Laboratories Biologics and Biosimilars Sales by Application in 2021
4.19.7 United Laboratories Biologics and Biosimilars Sales by Geographic Area in 2021
4.19.8 United Laboratories Recent Development
5 Breakdown Data by Type
5.1 Global Biologics and Biosimilars Sales by Type (2017-2028)
5.1.1 Global Biologics and Biosimilars Sales by Type (2017-2022)
5.1.2 Global Biologics and Biosimilars Sales Forecast by Type (2023-2028)
5.1.3 Global Biologics and Biosimilars Sales Market Share by Type (2017-2028)
5.2 Global Biologics and Biosimilars Revenue Forecast by Type (2017-2028)
5.2.1 Global Biologics and Biosimilars Revenue by Type (2017-2022)
5.2.2 Global Biologics and Biosimilars Revenue Forecast by Type (2023-2028)
5.2.3 Global Biologics and Biosimilars Revenue Market Share by Type (2017-2028)
5.3 Biologics and Biosimilars Average Selling Price (ASP) by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global Biologics and Biosimilars Sales by Application (2017-2028)
6.1.1 Global Biologics and Biosimilars Sales by Application (2017-2022)
6.1.2 Global Biologics and Biosimilars Sales Forecast by Application (2023-2028)
6.1.3 Global Biologics and Biosimilars Sales Market Share by Application (2017-2028)
6.2 Global Biologics and Biosimilars Revenue Forecast by Application (2017-2028)
6.2.1 Global Biologics and Biosimilars Revenue by Application (2017-2022)
6.2.2 Global Biologics and Biosimilars Revenue Forecast by Application (2023-2028)
6.2.3 Global Biologics and Biosimilars Revenue Market Share by Application (2017-2028)
6.3 Biologics and Biosimilars Average Selling Price (ASP) by Application (2017-2028)
7 North America
7.1 North America Biologics and Biosimilars Market Size YoY Growth 2017-2028
7.2 North America Biologics and Biosimilars Market Facts & Figures by Country
7.2.1 North America Biologics and Biosimilars Sales by Country (2017-2028)
7.2.2 North America Biologics and Biosimilars Revenue by Country (2017-2028)
7.3 North America Biologics and Biosimilars Sales by Type
7.4 North America Biologics and Biosimilars Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Biologics and Biosimilars Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Biologics and Biosimilars Market Facts & Figures by Region
8.2.1 Asia-Pacific Biologics and Biosimilars Sales by Region (2017-2028)
8.2.2 Asia-Pacific Biologics and Biosimilars Revenue by Region (2017-2028)
8.3 Asia-Pacific Biologics and Biosimilars Sales by Type
8.4 Asia-Pacific Biologics and Biosimilars Sales by Application
9 Europe
9.1 Europe Biologics and Biosimilars Market Size YoY Growth 2017-2028
9.2 Europe Biologics and Biosimilars Market Facts & Figures by Country
9.2.1 Europe Biologics and Biosimilars Sales by Country (2017-2028)
9.2.2 Europe Biologics and Biosimilars Revenue by Country (2017-2028)
9.3 Europe Biologics and Biosimilars Sales by Type
9.4 Europe Biologics and Biosimilars Sales by Application
10 Latin America
10.1 Latin America Biologics and Biosimilars Market Size YoY Growth 2017-2028
10.2 Latin America Biologics and Biosimilars Market Facts & Figures by Country
10.2.1 Latin America Biologics and Biosimilars Sales by Country (2017-2028)
10.2.2 Latin America Biologics and Biosimilars Revenue by Country (2017-2028)
10.3 Latin America Biologics and Biosimilars Sales by Type
10.4 Latin America Biologics and Biosimilars Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Biologics and Biosimilars Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
11.2.1 Middle East and Africa Biologics and Biosimilars Sales by Country (2017-2028)
11.2.2 Middle East and Africa Biologics and Biosimilars Revenue by Country (2017-2028)
11.3 Middle East and Africa Biologics and Biosimilars Sales by Type
11.4 Middle East and Africa Biologics and Biosimilars Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Biologics and Biosimilars Supply Chain Analysis
12.2 Biologics and Biosimilars Key Raw Materials and Upstream Suppliers
12.3 Biologics and Biosimilars Clients Analysis
12.4 Biologics and Biosimilars Sales Channel and Sales Model Analysis
12.4.1 Biologics and Biosimilars Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Biologics and Biosimilars Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Biologics and Biosimilars Distributors
13 Market Dynamics
13.1 Biologics and Biosimilars Industry Trends
13.2 Biologics and Biosimilars Market Drivers
13.3 Biologics and Biosimilars Market Challenges
13.4 Biologics and Biosimilars Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Manufacturers of Monoclonal Antibodies
Table 3. Major Manufacturers of Interferon
Table 4. Major Manufacturers of Erythropoietin
Table 5. Major Manufacturers of Insulin
Table 6. Major Manufacturers of Vaccines
Table 7. Major Manufacturers of Others
Table 8. Global Biologics and Biosimilars Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Biologics and Biosimilars Market Size by Region (US$ Million): 2021 VS 2022 VS 2028
Table 10. Global Biologics and Biosimilars Sales by Region (2017-2022) & (K Units)
Table 11. Global Biologics and Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 12. Global Biologics and Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Biologics and Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Biologics and Biosimilars Sales by Manufacturer (2017-2022) & (K Units)
Table 15. Global Biologics and Biosimilars Sales Share by Manufacturer (2017-2022)
Table 16. Biologics and Biosimilars Revenue by Manufacturer (2017-2022) & (US$ Million)
Table 17. Biologics and Biosimilars Revenue Share by Manufacturer (2017-2022)
Table 18. Key Manufacturers Biologics and Biosimilars Price (2017-2022) & (USD/Unit)
Table 19. Ranking of Global Top Biologics and Biosimilars Manufacturers by Revenue (US$ Million) in 2021
Table 20. Global Biologics and Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 21. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biologics and Biosimilars as of 2021)
Table 22. Biologics and Biosimilars Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Biologics and Biosimilars Product Type
Table 24. Date of International Manufacturers Enter into Biologics and Biosimilars Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Roche Corporation Information
Table 27. Roche Description and Business Overview
Table 28. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 29. Roche Biologics and Biosimilars Product
Table 30. Roche Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 31. Roche Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 32. Roche Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 33. Roche Recent Development
Table 34. Amgen Corporation Information
Table 35. Amgen Description and Business Overview
Table 36. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 37. Amgen Biologics and Biosimilars Product
Table 38. Amgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 39. Amgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 40. Amgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 41. Amgen Recent Development
Table 42. AbbVie Corporation Information
Table 43. AbbVie Description and Business Overview
Table 44. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. AbbVie Biologics and Biosimilars Product
Table 46. AbbVie Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 47. AbbVie Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 48. AbbVie Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 49. AbbVie Recent Development
Table 50. Sanofi-Aventis Corporation Information
Table 51. Sanofi-Aventis Description and Business Overview
Table 52. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 53. Sanofi-Aventis Biologics and Biosimilars Product
Table 54. Sanofi-Aventis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 55. Sanofi-Aventis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 56. Sanofi-Aventis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 57. Sanofi-Aventis Recent Development
Table 58. Johnson & Johnson Corporation Information
Table 59. Johnson & Johnson Description and Business Overview
Table 60. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 61. Johnson & Johnson Biologics and Biosimilars Product
Table 62. Johnson & Johnson Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 63. Johnson & Johnson Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 64. Johnson & Johnson Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 65. Johnson & Johnson Recent Development
Table 66. Pfizer Corporation Information
Table 67. Pfizer Description and Business Overview
Table 68. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 69. Pfizer Biologics and Biosimilars Product
Table 70. Pfizer Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 71. Pfizer Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 72. Pfizer Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 73. Novo Nordisk Corporation Information
Table 74. Novo Nordisk Description and Business Overview
Table 75. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 76. Novo Nordisk Biologics and Biosimilars Product
Table 77. Novo Nordisk Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 78. Novo Nordisk Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 79. Novo Nordisk Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 80. Eli Lilly Corporation Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 83. Eli Lilly Biologics and Biosimilars Product
Table 84. Eli Lilly Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 85. Eli Lilly Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 86. Eli Lilly Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 87. Novartis Corporation Information
Table 88. Novartis Description and Business Overview
Table 89. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. Novartis Biologics and Biosimilars Product
Table 91. Novartis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 92. Novartis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 93. Novartis Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 94. Merck Corporation Information
Table 95. Merck Description and Business Overview
Table 96. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Merck Biologics and Biosimilars Product
Table 98. Merck Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 99. Merck Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 100. Merck Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 101. 3sbio Corporation Information
Table 102. 3sbio Description and Business Overview
Table 103. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 104. 3sbio Biologics and Biosimilars Product
Table 105. 3sbio Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 106. 3sbio Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 107. 3sbio Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 108. Changchun High Tech Corporation Information
Table 109. Changchun High Tech Description and Business Overview
Table 110. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 111. Changchun High Tech Biologics and Biosimilars Product
Table 112. Changchun High Tech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 113. Changchun High Tech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 114. Changchun High Tech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 115. CP Guojian Corporation Information
Table 116. CP Guojian Description and Business Overview
Table 117. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 118. CP Guojian Biologics and Biosimilars Product
Table 119. CP Guojian Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 120. CP Guojian Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 121. CP Guojian Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 122. Biotech Corporation Information
Table 123. Biotech Description and Business Overview
Table 124. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 125. Biotech Biologics and Biosimilars Product
Table 126. Biotech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 127. Biotech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 128. Biotech Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 129. Gelgen Corporation Information
Table 130. Gelgen Description and Business Overview
Table 131. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 132. Gelgen Biologics and Biosimilars Product
Table 133. Gelgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 134. Gelgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 135. Gelgen Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 136. Innovent Corporation Information
Table 137. Innovent Description and Business Overview
Table 138. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 139. Innovent Biologics and Biosimilars Product
Table 140. Innovent Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 141. Innovent Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 142. Innovent Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Geographic Area in 2021
Table 143. Dong Bao Corporation Information
Table 144. Dong Bao Description and Business Overview
Table 145. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 146. Dong Bao Biologics and Biosimilars Product
Table 147. Dong Bao Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Product in 2021
Table 148. Dong Bao Biologics and Biosimilars Sales Proportion of Biologics and Biosimilars by Application in 2021
Table 149. Dong Bao Biologics and Biosimilars Sales Proportion of Biologics
  • Global Biologics and Biosimilars Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 147
    According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the futu......
  • Global Biosimilar Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Biosimilar Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Biosimilar Drug market. Biosimilar Drug are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Biologics and Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 147
    According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period. Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin......
  • Global Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 2680 Onwards        Pages: 167
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 3280 Onwards        Pages: 133
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Biosimilars market: According to our latest research, the global Biosimilars market looks promising in the next 5 years. As of 2022, the global Biosimilars market was estimated at USD 8203.97 million, and it's anticipated to reach USD 40650.01 million in 2028, with a CAGR of 30.57% during the forecast years. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA?approved biologic product......
  • Global Biologics and Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 3280 Onwards        Pages: 134
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biologics and Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 2680 Onwards        Pages: 160
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biosimilar Monoclonal Antibodies Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Biosimilar Monoclonal Antibodies market: According to our latest research, the global Biosimilar Monoclonal Antibodies market looks promising in the next 5 years. As of 2022, the global Biosimilar Monoclonal Antibodies market was estimated at USD 5156.19 million, and it's anticipated to reach USD 14274.14 million in 2028, with a CAGR of 18.5% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs